Regeneron is acquiring Checkmate Pharmaceuticals and entered a clinical trial collaboration with SpringWorks Therapeutics to evaluate REGN5458 in multiple myeloma in combination with nirogacestat.
Janssen Victorious in Arbitration Battle Vs. Genmab over Darzalex Royalties
Expirations, FDA, Janssen, Johnson & Johnson, Multiple Myeloma, Patent, Patent Challenges, Patent Claims, Patent Disputes, Patent Exclusivity, Patent Expirations, Patent Infringement, Patent Lawsuits, Patent Licensing, Patent Litigation, Patent Protection, Patents, Therapeutics, U.S. Patent OfficeApr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment […]